| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Epelsiban besylate primarily targets the oxytocin receptor (OTR), a Gq-protein coupled receptor. It acts as a competitive antagonist, blocking oxytocin-induced signaling. Epelsiban exhibits >31,000-fold selectivity for the oxytocin receptor over the vasopressin V1a receptor and >2,500-fold selectivity over V1b and V2 receptors. By inhibiting OTR-mediated Gq signaling, epelsiban decreases inositol 1,4,5-trisphosphate (IP3) production and calcium flux. It is a non-peptide antagonist with high oral bioavailability.
|
|---|---|
| ln Vitro |
In vitro, Epelsiban binds to the human oxytocin receptor with a pKi of 9.9 (Ki ≈ 0.13 nM). It inhibits oxytocin-induced calcium flux in HEK293 cells expressing human OTR with an IC50 of 9.2 nM. Epelsiban shows >31,000-fold selectivity over the human V1a receptor and >2,500-fold selectivity over V1b and V2 receptors. It competitively inhibits OTR-mediated IP3 production with single-site competitive binding kinetics. Epelsiban is a potent, selective, and orally bioavailable OTR antagonist.
|
| ln Vivo |
In vivo, Epelsiban is orally active and well-tolerated. In phase I clinical trials, total daily doses of 600 and 900 mg were generally well tolerated with no significant safety concerns. Epelsiban inhibits oxytocin-induced uterine contractions in animal models. It has been investigated for the treatment of premature ejaculation and women infertility due to adenomyosis. The compound demonstrates dose-dependent pharmacokinetics with a half-life suitable for once-daily dosing.
|
| Enzyme Assay |
For radioligand binding assays, membrane fractions from HEK293 cells expressing human OTR are incubated with [3H]oxytocin in the presence of Epelsiban at varying concentrations. Reactions are performed in buffer containing 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, and 0.1% BSA at 25°C for 60-120 minutes. Bound radioligand is separated by rapid filtration and quantified by scintillation counting.
|
| Cell Assay |
For functional assays, HEK293 cells expressing human OTR are loaded with Fluo-4 dye and treated with Epelsiban at varying concentrations for 10 minutes, followed by oxytocin stimulation. Calcium flux is measured by microplate reader. For IP3 assays, cells are labeled with [3H]myo-inositol, and IP3 production is measured by ion-exchange chromatography.
|
| Animal Protocol |
For in vivo studies, rats or mice are administered Epelsiban orally at doses ranging from 1-100 mg/kg. Oxytocin-induced uterine contractions are measured in anesthetized animals. For pharmacokinetic studies, plasma samples are collected at various time points, and Epelsiban is quantified by LC-MS/MS.
|
| Molecular Formula |
C36H44N4O7S
|
|---|---|
| Molecular Weight |
676.82216835022
|
| Exact Mass |
676.293
|
| CAS # |
1159097-48-9
|
| Related CAS # |
872599-83-2;1159097-48-9 (besylate);
|
| PubChem CID |
51352566
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
155
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
48
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
S(C1C=CC=CC=1)(=O)(=O)O.O=C1[C@@H](C2CC3C=CC=CC=3C2)NC([C@@H]([C@@H](C)CC)N1[C@@H](C(N1CCOCC1)=O)C1=CC=C(C)N=C1C)=O
|
| InChi Key |
BEWUOCYETMDWGE-FKDQZALLSA-N
|
| InChi Code |
InChI=1S/C30H38N4O4.C6H6O3S/c1-5-18(2)26-28(35)32-25(23-16-21-8-6-7-9-22(21)17-23)29(36)34(26)27(24-11-10-19(3)31-20(24)4)30(37)33-12-14-38-15-13-33;7-10(8,9)6-4-2-1-3-5-6/h6-11,18,23,25-27H,5,12-17H2,1-4H3,(H,32,35);1-5H,(H,7,8,9)/t18-,25+,26+,27+;/m0./s1
|
| Chemical Name |
benzenesulfonic acid;(3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethylpyridin-3-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4775 mL | 7.3875 mL | 14.7750 mL | |
| 5 mM | 0.2955 mL | 1.4775 mL | 2.9550 mL | |
| 10 mM | 0.1477 mL | 0.7387 mL | 1.4775 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.